Company Encyclopedia
View More
name
Ascentage Pharma Group International ADR - W/I
AAPGV.US
1.946 T
AAPGV.USMarket value -Rank by Market Cap -/-

Financial Score

04/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking182/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-53.13%E
    • Profit Margin-39.90%E
    • Gross Margin98.17%A
  • Growth ScoreA
    • Revenue YoY244.05%A
    • Net Profit YoY59.90%B
    • Total Assets YoY6.50%B
    • Net Assets YoY29.39%A
  • Cash ScoreB
    • Cash Flow Margin-250.64%D
    • OCF YoY244.05%A
  • Operating ScoreD
    • Turnover0.3D
  • Debt ScoreE
    • Gearing Ratio75.01%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Ascentage rises on progress of olverembatinib for blood cancer treatment

    Ascentage Pharma's stock rose 6.8% to HK$65 following FDA and EMA clearance for a Phase III study of olverembatinib for blood cancer treatment. The POLARIS-1 trial will assess the drug's efficacy and safety in combination with chemotherapy for leukemia. The stock is up 37% YTD, while the Hang Seng Biotech Index is up 78.8%.

    Reuters·
    US
    AAPGV
    0.00%
    US
    AAPG
    +1.22%
    Reuters·
    US
    AAPGV
    0.00%
    US
    AAPG
    +1.22%

    Ascentage Pharma Wins FDA and EMA Clearance for Global Phase III Study of Olverembatinib in Ph+ ALL

    Ascentage Pharma has received FDA and EMA clearance for a global Phase III study of olverembatinib in Ph+ ALL. This approval allows patient enrollment across multiple countries, potentially accelerating olverembatinib's registration in the US and Europe.

    Reuters·
    US
    AAPG
    +1.22%
    US
    AAPGV
    0.00%
    HK
    06855
    +3.53%
    Reuters·
    US
    AAPG
    +1.22%
    US
    AAPGV
    0.00%
    HK
    06855
    +3.53%

    Ascentage Pharma’s Olverembatinib Shows Promise in Rare GIST Treatment

    Ascentage Pharma announced promising Phase Ib trial results for olverembatinib in treating SDH-deficient GIST, showing significant efficacy and safety. The study, published in Signal Transduction and Targeted Therapy, reported an 84.6% clinical benefit rate and 25.7 months median progression-free survival. Despite this, analysts rate AAPG stock as a Sell due to financial challenges, including high debt and negative profitability. Ascentage Pharma focuses on novel cancer therapies, with olverembatinib approved in China for CML and under evaluation for GIST.

    Tip Ranks·
    US
    AAPGV
    0.00%
    US
    AAPG
    +1.22%
    Tip Ranks·
    US
    AAPGV
    0.00%
    US
    AAPG
    +1.22%

    Certain Ordinary Shares of Ascentage Pharma Group International are subject to a Lock-Up Agreement Ending on 16-OCT-2025.

    Certain Ordinary Shares of Ascentage Pharma Group International are under a Lock-Up Agreement that will end on 16-OCT-2025. The lock-up period lasts for 91 days, from 17-JUL-2025 to 16-OCT-2025. During this time, the Vendor and associated parties are restricted from selling or disposing of any equity securities of the Company without prior written consent from the Placing Agents.

    marketscreener·
    US
    AAPG
    +1.22%
    US
    AAPGV
    0.00%
    marketscreener·
    US
    AAPG
    +1.22%
    US
    AAPGV
    0.00%

    Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates | AAPG Stock News

    Ascentage Pharma reported its interim unaudited financial results for the first half of 2025, highlighting a 93% increase in Olverembatinib sales to $30.3 million, driven by expanded NRDL coverage. The company commenced sales of Lisaftoclax after its approval in July 2025 and is actively conducting nine registrational clinical trials, with three cleared by the FDA. A successful financing round raised $190.1 million, enhancing its resources for commercialization and development efforts. The company continues to advance its innovative cancer therapies globally.

    StockTitan·
    US
    AAPG
    +1.22%
    HK
    06855
    +3.53%
    StockTitan·
    US
    AAPG
    +1.22%
    HK
    06855
    +3.53%
    © 2025 Longbridge｜Disclaimer